Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.38 | N/A | -19.50% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.38 | N/A | -19.50% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current performance but remains focused on future growth. They did not provide specific guidance for upcoming quarters.
Management acknowledged the challenges faced in the quarter.
They emphasized a focus on long-term goals despite short-term setbacks.
Alnylam Pharmaceuticals reported a wider-than-expected loss in EPS, which contributed to a 2.53% decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's near-term outlook. Management's defensive tone suggests they are aware of the challenges ahead but are committed to long-term strategies.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NEXTERA ENERGY INC
Apr 29, 2011